home > ict

International Clinical Trials


International Clinical Trials (ICT) is a specialist journal designed to provide global coverage of key topics pertinent to the clinical trials sector.

Published quarterly, and edited by Dr Graham Hughes, the journal offers a platform of communication and information-sharing for executive and strategic decision-makers, seeking out new trends and marketing opportunities, as well as putting a spotlight on the latest innovations coming to market. ICT is specifically designed to be of interest to those actively seeking to source services for improved efficiency in what is an increasingly competitive market.

For further information please contact:

Nick Matthews   

Rupert Gilbey


View the digital version of ICT

Featured in this issue
Sample Integrity

Piece of the Action

As vital scientific assets for current and future research, clinical trial samples must be properly handled, from collection to transport to storage. Lori Ball of BioStorage Technologies makes the case for a strategic sample management plan to be considered upfront in the study design.
Regulatory & Business Practice
Antibiotics R&D

Back to Health

A turbulent period for antibiotics development could be drawing to a close. Jon Bruss and Brian Murphy at Medpace describe how the public health crisis over multi-drug resistance has triggered an R&D surge by smaller biotechs and regulators.
Adaptive Designs

Changing Priorities

Growing steadily over the last decade, adaptive designs are being used for studies across industry and considered for new treatment assignments. Shyama Ghosh and Alvaro Arjona at Thomson Reuters provide an update on their use.

Edited by
Dr Graham Hughes
Consultant in

Published quarterly in
February, May,
August and November
Banner of Publication and Clinical Trials Disclosure.ICT on Samedan
Banner of Late phase research.ICT on Samedan
Banner of Clintec.ICT  on Samedan
Industry Events

10th Late Phase Research and Real-World Data

22-23 May 2014, Dublin, Ireland

The 10th Late Phase Research/Real-World Data conference combines two important topics into one comprehensive platform.
More info >>

News and Press Releases

Reinventing Buffer Screening with Avacta’s Optim Technology

Avacta’s Optim protein stability analysis technology is helping researchers at Manchester University to approach buffer selection in an entirely new way. Dr Tom Jowitt, Manager of the University’s Biomolecular Analysis Core Facility, explained: “Academic institutions tend to work by word of mouth on protein projects, sticking to buffer conditions they are familiar with, or that have been used on previous projects within the laboratory. The buffers in use are often far from optimal for the protein of interest, but a lack of understanding of how to optimise buffer conditions means that these issues are rarely addressed.”
More info >>

air transport logo


White Papers

Choosing the Right CMO for HPAPI Manufacturing


Over the past few years a steady stream of contract manufacturing organizations (CMO) have added high potency active pharmaceutical ingredient (HPAPI) production capacity. The expansions give biopharma executives charged with selecting HPAPI production partners an unprecedented number of options, but all this choice creates a problem — which CMO should you pick when each is touting similar technical capabilities?
More info >>

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement